Peer Review reports
From: CA916798 predicts poor prognosis and promotes Gefitinib resistance for lung adenocarcinoma
| Original Submission | ||
|---|---|---|
| 4 Nov 2022 | Submitted | Original manuscript |
| 17 Jan 2023 | Reviewed | Reviewer Report |
| 23 Jan 2023 | Reviewed | Reviewer Report |
| 8 Feb 2023 | Author responded | Author comments - Xiangdong Zhou |
| Resubmission - Version 2 | ||
| 8 Feb 2023 | Submitted | Manuscript version 2 |
| 13 Feb 2023 | Author responded | Author comments - Xiangdong Zhou |
| Resubmission - Version 3 | ||
| 13 Feb 2023 | Submitted | Manuscript version 3 |
| 14 Feb 2023 | Author responded | Author comments - Xiangdong Zhou |
| Resubmission - Version 4 | ||
| 14 Feb 2023 | Submitted | Manuscript version 4 |
| 22 Feb 2023 | Author responded | Author comments - Xiangdong Zhou |
| Resubmission - Version 5 | ||
| 22 Feb 2023 | Submitted | Manuscript version 5 |
| 6 Mar 2023 | Reviewed | Reviewer Report |
| 13 Mar 2023 | Reviewed | Reviewer Report |
| Resubmission - Version 6 | ||
| Submitted | Manuscript version 6 | |
| Publishing | ||
| 13 Mar 2023 | Editorially accepted | |
| 23 Mar 2023 | Article published | 10.1186/s12885-023-10735-3 |
You can find further information about peer review here.